These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30203471)

  • 1. Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal.
    Askarizadeh A; Butler AE; Badiee A; Sahebkar A
    J Cell Physiol; 2019 Feb; 234(2):1219-1229. PubMed ID: 30203471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.
    Catapano AL
    Curr Vasc Pharmacol; 2012 Mar; 10(2):257-67. PubMed ID: 22022768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of nanotechnology to improve the therapeutic benefits of statins.
    Korani S; Korani M; Bahrami S; Johnston TP; Butler AE; Banach M; Sahebkar A
    Drug Discov Today; 2019 Feb; 24(2):567-574. PubMed ID: 30292917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins: Pharmacokinetics, Pharmacodynamics and Cost-Effectiveness Analysis.
    Ricci G; Ciccone MM; Giordano P; Cortese F
    Curr Vasc Pharmacol; 2019; 17(3):213-221. PubMed ID: 29984667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability.
    Hashem FM; Al-Sawahli MM; Nasr M; Ahmed OA
    Drug Des Devel Ther; 2015; 9():3141-52. PubMed ID: 26150693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the therapeutic potential of statins by means of nanotechnology enabled drug delivery systems.
    Romana B; Batger M; Prestidge CA; Colombo G; Sonvico F
    Curr Top Med Chem; 2014; 14(9):1182-93. PubMed ID: 24678704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interactions between statins and fibrates.
    Corsini A; Bellosta S; Davidson MH
    Am J Cardiol; 2005 Nov; 96(9A):44K-49K; discussion 34K-35K. PubMed ID: 16291014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do statins beneficially or adversely affect glucose homeostasis?
    Kostapanos MS; Liamis GL; Milionis HJ; Elisaf MS
    Curr Vasc Pharmacol; 2010 Sep; 8(5):612-31. PubMed ID: 20507274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats.
    Zhang Z; Bu H; Gao Z; Huang Y; Gao F; Li Y
    Int J Pharm; 2010 Jul; 394(1-2):147-53. PubMed ID: 20435111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins: Then and Now.
    Toth PP; Banach M
    Methodist Debakey Cardiovasc J; 2019; 15(1):23-31. PubMed ID: 31049146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G5 PAMAM dendrimer versus liposome: a comparison study on the in vitro transepithelial transport and in vivo oral absorption of simvastatin.
    Qi R; Zhang H; Xu L; Shen W; Chen C; Wang C; Cao Y; Wang Y; van Dongen MA; He B; Wang S; Liu G; Banaszak Holl MM; Zhang Q
    Nanomedicine; 2015 Jul; 11(5):1141-51. PubMed ID: 25791813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
    Lopez LM
    J Am Pharm Assoc (2003); 2005; 45(4):503-13. PubMed ID: 16128507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.
    Schachter M
    Fundam Clin Pharmacol; 2005 Feb; 19(1):117-25. PubMed ID: 15660968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing Solubility and Bioavailability of Rosuvastatin into Self Nanoemulsifying Drug Delivery System.
    Karasulu HY; Gundogdu E; Turk UO; Turgay T; Apaydin S; Simsir IY; Yilmaz C; Karasulu E
    Curr Drug Deliv; 2018; 15(7):1072-1082. PubMed ID: 29484996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid Testing and Statin Dosing After Acute Myocardial Infarction.
    Wang WT; Hellkamp A; Doll JA; Thomas L; Navar AM; Fonarow GC; Julien HM; Peterson ED; Wang TY
    J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29371200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic effects of statins: new therapeutic targets in drug design.
    Bedi O; Dhawan V; Sharma PL; Kumar P
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jul; 389(7):695-712. PubMed ID: 27146293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of statins on the kidneys in patients with type 2 diabetes.
    Hanai K; Babazono T; Uchigata Y
    Clin Exp Nephrol; 2017 Aug; 21(4):633-642. PubMed ID: 27631405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?
    Tatham LM; Liptrott NJ; Rannard SP; Owen A
    Molecules; 2019 Jul; 24(15):. PubMed ID: 31344834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.